(NASDAQ: LBRX) Lb Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 71.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 105.58%.
Lb Pharmaceuticals's earnings in 2025 is N/A.On average, 5 Wall Street analysts forecast LBRX's earnings for 2025 to be -$67,867,371, with the lowest LBRX earnings forecast at -$75,619,016, and the highest LBRX earnings forecast at -$55,784,520. On average, 5 Wall Street analysts forecast LBRX's earnings for 2026 to be -$107,779,234, with the lowest LBRX earnings forecast at -$125,949,049, and the highest LBRX earnings forecast at -$87,661,388.
In 2027, LBRX is forecast to generate -$105,284,743 in earnings, with the lowest earnings forecast at -$116,031,801 and the highest earnings forecast at -$83,676,780.